Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Ohanian, Maro
[Clear All Filters]
2019
Richard-Carpentier G
,
Jabbour E
,
Short NJ
,
Rausch CR
,
Savoy JM
,
Bose P
,
Yilmaz M
,
Jain N
,
Borthakur G
,
Ohanian M
, et al.
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk. 2019.
PubMed
Google Scholar
2020
Abaza Y
,
Kantarjian H
,
Alwash Y
,
Borthakur G
,
Champlin R
,
Kadia T
,
Garcia-Manero G
,
Daver N
,
Ravandi F
,
Verstovsek S
, et al.
Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia.
Am J Hematol. 2020.
PubMed
Google Scholar
2022
Kadia TM
,
Reville PK
,
Wang X
,
Rausch CR
,
Borthakur G
,
Pemmaraju N
,
Daver NG
,
Dinardo CD
,
Sasaki K
,
Issa GC
, et al.
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
J Clin Oncol. 2022:JCO2102823.
PubMed
Google Scholar
2024
Short NJ
,
Jabbour EJ
,
Jain N
,
Senapati J
,
Nasr LFady
,
Haddad FG
,
Li Z
,
Hsiao Y-C
,
Yang JJ
,
Pemmaraju N
, et al.
A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Blood Adv. 2024.
PubMed
Google Scholar